{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T13:38:08Z","timestamp":1715953088655},"reference-count":56,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2010,11,30]],"date-time":"2010-11-30T00:00:00Z","timestamp":1291075200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["American J Hematol"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Few studies have evaluated prognostic factors among patients with multiple myeloma (MM) since new therapies have become available. Monthly zoledronic acid (ZOL) has been incorporated into many treatment regimens to reduce skeletal\u2010related events (SREs), but outcomes among patients receiving this bisphosphonate have not been well\u2010defined. The aim of this retrospective study was to determine baseline and on\u2010treatment prognostic factors in these patients. Data were collected from the date of diagnosis on 300 consecutive MM patients treated with ZOL. Median duration of ZOL was 18 months (range 1\u2013121 months). The skeletal morbidity rate was 0.116 events per patient year. Five\u2010year overall survival (OS) was 69%. Risk factors for shortened OS included SREs, increased serum creatinine, and International Staging System (ISS) Stage II or III. Thirty\u2010four (11%) patients showed worsening renal function. In 28 of these patients, ZOL was discontinued and restarted in half of these patients following a brief delay. Only 5 of the 34 patients showed worsening of their renal function. Fourteen patients (4.7%) developed osteonecrosis of the jaw (ONJ). All patients with ONJ are in remission or with stable disease except one patient who died of a myocardial infarction while in remission. Only two patients showed some worsening of ONJ despite of ongoing monthly ZOL. Overall, these results suggest that skeletal complications are an important prognostic factor for MM. Although ONJ and renal deterioration may infrequently occur with ZOL, most patients do not experience worsening of these conditions with ongoing treatment with this bisphosphonate. Am. J. Hematol., 2011. \u00a9 2010 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/ajh.21912","type":"journal-article","created":{"date-parts":[[2010,10,27]],"date-time":"2010-10-27T18:18:01Z","timestamp":1288203481000},"page":"25-30","source":"Crossref","is-referenced-by-count":18,"title":["Prognostic factors and jaw and renal complications among multiple myeloma patients treated with zoledronic acid"],"prefix":"10.1002","volume":"86","author":[{"given":"James R.","family":"Berenson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ori","family":"Yellin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adel","family":"Makary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald S.","family":"Gravenor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hank H.","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gargi H.","family":"Upadhyaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian W.","family":"Flinn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harry","family":"Staszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha M.","family":"Tiffany","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shamel","family":"Sanani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles M.","family":"Farber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Morganstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanessa","family":"Bolejack","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youram","family":"Nassir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James D.","family":"Hilger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashkan","family":"Sefaradi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albert","family":"Shamouelian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina A.","family":"Swift","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,11,30]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.0100"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-08-104984"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-10-116129"},{"key":"e_1_2_5_5_2","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1182\/blood.V91.7.2501","article-title":"Plasmablastic morphology\u2010an independent prognostic factor with clinical and laboratory correlates: Eastern Cooperative Oncology Group (ECOG) myeloma trial E9486 report by the ECOG myeloma laboratory group","volume":"7","author":"Greipp P","year":"1998","journal-title":"Blood"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0889-8588(05)70128-3"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.242"},{"key":"e_1_2_5_8_2","first-page":"300","article-title":"Staging and kinetics of multiple myeloma","volume":"13","author":"Durie B","year":"1986","journal-title":"Semin Oncol"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.12106"},{"key":"e_1_2_5_10_2","first-page":"291","article-title":"Bone destruction and hypercalcemia in plasma cell myeloma","volume":"13","author":"Mundy GR","year":"1986","journal-title":"Semin Oncol"},{"key":"e_1_2_5_11_2","first-page":"29","article-title":"Multiple myeloma: Review of 869 cases","volume":"50","author":"Kyle RA","year":"1975","journal-title":"Mayo Clin Proc"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.2.593"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00009"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2002.n.016"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.3816\/CGC.2005.n.009"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdg401"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V96.2.384"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403693"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.102.035295"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2005.25.144"},{"key":"e_1_2_5_22_2","first-page":"7505","article-title":"Survival in patients with multiple myeloma receiving zoledronic acid: Stratification by baseline bone alkaline phosphatase levels","volume":"24","author":"Berenson J","year":"2006","journal-title":"J Clin Oncol ASCO Ann Meet Proc"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02698044"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200507073530120"},{"key":"e_1_2_5_25_2","doi-asserted-by":"crossref","first-page":"15s","DOI":"10.1200\/jco.2010.28.15_suppl.8021","article-title":"Evaluating the effects of zoledronic acid on overall survival in patients with multiple myeloma: Results of the Medical Research Council (MRC) myeloma IX study","volume":"28","author":"Morgan G","year":"2010","journal-title":"J Clin Oncol"},{"issue":"1","key":"e_1_2_5_26_2","first-page":"S131","article-title":"Osteonecrosis of the jaw in patients with metastatic breast cancer (abstract 3057)","volume":"88","author":"Van Poznak CH","year":"2004","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"e_1_2_5_27_2","first-page":"555","article-title":"Osteonecrosis of the jaw in patients receiving intravenous bisphosphonate therapy (abstract 1218)","volume":"20","author":"Hoff AO","year":"2005","journal-title":"J Bone Miner Res"},{"key":"e_1_2_5_28_2","first-page":"1053","article-title":"Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates","volume":"20","author":"Van Poznak CH","year":"2006","journal-title":"Oncology"},{"key":"e_1_2_5_29_2","first-page":"1065","article-title":"The Van Poznak\/Estilo article reviewed","volume":"20","author":"Berenson JR","year":"2006","journal-title":"Oncology"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080759"},{"key":"e_1_2_5_31_2","first-page":"100","article-title":"Osteonecrosis of the jaw and bisphosphonates","volume":"353","author":"Woo SB","year":"2005","journal-title":"N Engl J Med"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2006-2036"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.14.1.65"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.02.116"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2006.06230.x"},{"key":"e_1_2_5_36_2","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double\u2010blind, comparative trial","volume":"7","author":"Rosen LS","year":"2001","journal-title":"Cancer J"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.V1261164"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0272-6386(03)00214-2"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1523-1755.2003.00071.x"},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200310233491721"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1E589"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.5414\/CNP61063"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn796"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U"},{"key":"e_1_2_5_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23783"},{"key":"e_1_2_5_47_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.62"},{"key":"e_1_2_5_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11701"},{"key":"e_1_2_5_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404806"},{"key":"e_1_2_5_50_2","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2008.174"},{"key":"e_1_2_5_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-2391(03)00720-1"},{"key":"e_1_2_5_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2004.02.004"},{"key":"e_1_2_5_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0278-2391(03)00328-8"},{"key":"e_1_2_5_54_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200507073530120"},{"key":"e_1_2_5_55_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn526"},{"key":"e_1_2_5_56_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.9300"},{"key":"e_1_2_5_57_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-147884"}],"container-title":["American Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fajh.21912","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ajh.21912","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T14:18:28Z","timestamp":1697465908000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ajh.21912"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,11,30]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1002\/ajh.21912"],"URL":"https:\/\/doi.org\/10.1002\/ajh.21912","archive":["Portico"],"relation":{},"ISSN":["0361-8609","1096-8652"],"issn-type":[{"value":"0361-8609","type":"print"},{"value":"1096-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,11,30]]}}}